Outlook Therapeutics Sells 8.54M Shares to GMS Ventures in Direct Offering
OTLK has more than doubled off its 52-week low of $0.161 on elevated volume (2.4× avg).
Summary
Outlook Therapeutics completed a registered direct offering, selling 8.54 million common shares to GMS Ventures and Investments. This follows an earlier 424B5 filing today that disclosed a $4.9 million direct offering at $0.5855 per share. The company, which recently received a going concern warning, continues to raise capital through dilutive offerings to fund operations. This offering provides needed cash, but at a discount to the current market price, contributing to ongoing share dilution.
At the time of this announcement, OTLK was trading at $0.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $88.2M. The 52-week trading range was $0.16 to $3.39. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.